Heat shock proteins as targets in oncology

Clinical and Translational Oncology

Volumn 12, Issue 3, 2010, Pages 166-173

  Giménez Ortiz, Alejandra ^a   Montalar Salcedo, Joaquín ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

Author keywords

17 AAG; Cancer; Chaperones; HSP; Hsp90 inhibitors

Indexed keywords

ADENOSINE TRIPHOSPHATE; ANSAMYCIN DERIVATIVE; B RAF KINASE; BCR ABL PROTEIN; BORTEZOMIB; CD135 ANTIGEN; CHAPERONE; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GELDANAMYCIN; GEMCITABINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HEAT SHOCK PROTEIN 90 INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMATINIB; IRINOTECAN; NPM ALK KINASE; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN TYROSINE KINASE; RECEPTOR TYROSINE KINASE MET; SORAFENIB; TANESPIMYCIN; TRASTUZUMAB; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CELLULAR STRESS RESPONSE; CHEMOTHERAPY INDUCED EMESIS; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COLON CANCER; CONFORMATIONAL TRANSITION; DIARRHEA; DRUG SAFETY; DRUG SENSITIVITY; DRUG TARGETING; FATIGUE; GENE EXPRESSION; GLIOBLASTOMA; HUMAN; KIDNEY CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE MYELOMA; NAUSEA; ONCOLOGY; PROSTATE CANCER; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR CELL;

ANIMALS; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; HEAT-SHOCK PROTEINS; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 77952167700     PISSN: 1699048X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12094-010-0486-8     Document Type: Review

References (54)

1. W.J. Welch J.R. Feramisco 1982 Purification of the major mammalian heat shock proteins J Biol Chem 257 14949 14959 1:CAS:528:DyaL38XmtFSruro%3D 7174676
2. J.P. Hendrick F.U. Hartl 1993 Molecular chaperone functions of heat-shock proteins Annu Rev Biochem 62 349 384 10.1146/annurev.bi.62.070193.002025 1:CAS:528:DyaK3sXlsFCjurw%3D 8102520
3. S.J. Felts B.A. Owen P. Nguyen, et al. 2000 The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties J Biol Chem 275 3305 3312 10.1074/jbc.275.5.3305 1:CAS:528:DC%2BD3cXhtVygsLY%3D 10652318 (Pubitemid 30083032)
4. D.R. Ciocca S.K. Calderwood 2005 Heat shock proteins in cancers: diagnostic, prognostic, predictive, and treatment implications Cell Stress Chaperones 10 86 103 10.1379/CSC-99r.1 1:CAS:528:DC%2BD2MXmsFymur4%3D 16038406 (Pubitemid 40942470)
5. L. Neckers 2002 HSP90 inhibitors as novel cancer chemotherapeutic agents Trends Mol Med 8 S55 S61 10.1016/S1471-4914(02)02316-X 1:CAS:528: DC%2BD38XitlGhsb4%3D 11927289 (Pubitemid 34297080)
6. W.C. Hahn R.A. Weinberg 2002 Modelling the molecular circuitry of cancer Nat Rev Cancer 2 331 341 10.1038/nrc795 1:CAS:528:DC%2BD38Xkt1eltLc%3D 12044009
7. H. Kitano 2003 Cancer robustness: tumour tactics Nature 426 125 10.1038/426125a 1:CAS:528:DC%2BD3sXovVKmtrY%3D 14614483 (Pubitemid 37442564)
8. P. Workman 2003 Strategies for treating cancers caused by multiple genome abnormalities: from concepts to cures? Curr Opin Investig Drugs 4 1410 1415 1:CAS:528:DC%2BD2cXht1eqtLs%3D 14763125
9. F. Ritossa 1962 A new puffing pattern induced by temperature and DNP in Drosophila Experimentia 18 571 573 10.1007/BF02172188 1:CAS:528: DyaF3sXivVOgtw%3D%3D
10. F.U. Hartl M. Hayer-Hartl 2002 Molecular chaperones in the cytosol: from nascent chain to folded protein Science 295 1852 1858 10.1126/science.1068408 1:CAS:528:DC%2BD38XhvFClsL4%3D 11884745 (Pubitemid 34214115)
11. L. Whitesell S.L. Lindquist 2005 HSP90 and the chaperoning of cancer Nat Rev Cancer 5 761 772 10.1038/nrc1716 1:CAS:528:DC%2BD2MXhtVGjs7bF 16175177 (Pubitemid 41400776)
12. http://www.picard.ch/downloads/Hsp90interactors.pdf
13. P. Connell C.A. Ballinger J. Jiang, et al. 2001 The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins Nat Cell Biol 3 93 96 10.1038/35050618 1:CAS:528:DC%2BD3MXkslGqsQ%3D%3D 11146632 (Pubitemid 32114838)
14. D. Hanahan R.A. Weinberg 2000 The hallmarks of cancer Cell 100 57 70 10.1016/S0092-8674(00)81683-9 1:CAS:528:DC%2BD3cXks1CktA%3D%3D 10647931
15. P. Workman 2004 Combinatorial attack on multistep oncogenesis by inhibiting the Hsp90 molecular chaperone Cancer Lett 206 149 157 10.1016/j.canlet.2003.08.032 1:CAS:528:DC%2BD2cXhvFaiu7s%3D 15013520 (Pubitemid 38317285)
16. C. Queitsch T.A. Sangster S. Lindquist 2002 Hsp90 as a capacitor of phenotypic variation Nature 417 618 624 10.1038/nature749 1:CAS:528: DC%2BD38Xkt1ektrk%3D 12050657 (Pubitemid 34614814)
17. S.J. Felts B.A. Owen P. Nguyen, et al. 2000 The hsp90-related protein TRAP1 is a mitochondrial protein with distinct functional properties J Biol Chem 275 3305 3312 10.1074/jbc.275.5.3305 1:CAS:528:DC%2BD3cXhtVygsLY%3D 10652318 (Pubitemid 30083032)
18. N. Grammatikakis A. Vultur C.V. Ramana, et al. 2002 The role of Hsp90N, a new member of the Hsp90 family, in signal transduction and neoplastic transformation J Biol Chem 277 8312 8320 10.1074/jbc.M109200200 1:CAS:528:DC%2BD38XitFymt7s%3D 11751906 (Pubitemid 34968291)
19. C. Prodromou S.M. Roe R. O'Brien, et al. 1997 Identification and structural characterization of the ATP/ADP-binding site in the Hsp90 molecular chaperone Cell 90 65 75 10.1016/S0092-8674(00)80314-1 1:CAS:528: DyaK2sXkslShtLc%3D 9230303 (Pubitemid 28009419)
20. L.H. Pearl C. Prodromou P. Workman 2008 The Hsp90 molecular chaperone: an open and shut case for treatment Biochem J 410 439 453 10.1042/BJ20071640 1:CAS:528:DC%2BD1cXisVWgtrs%3D 18290764 (Pubitemid 351429015)
21. P. Connell C.A. Ballinger J. Jiang, et al. 2001 The co-chaperone CHIP regulates protein triage decisions mediated by heat-shock proteins Nat Cell Biol 3 93 96 10.1038/35050618 1:CAS:528:DC%2BD3MXkslGqsQ%3D%3D 11146632 (Pubitemid 32114838)
22. S. Sharp P. Workman 2006 Inhibitors of the HSP90 molecular chaperone: current status Adv Cancer Res 95 323 348 10.1016/S0065-230X(06)95009-X 1:CAS:528:DC%2BD1cXhvVCisLs%3D 16860662 (Pubitemid 44088424)
23. L. Neckers S.P. Ivy 2003 Heat shock protein 90 Curr Opin Oncol 15 419 424 10.1097/00001622-200311000-00003 1:CAS:528:DC%2BD3sXptVCmsbg%3D 14624223 (Pubitemid 38147036)
24. P. Bonvini T. Gastaldi B. Falini A. Rosolen 2002 Nucleophosmin-anaplastic lymphoma kinase (NPM-ALK), a novel Hsp90-client tyrosine kinase: down-regulation of NPM-ALK expression and tyrosine phosphorylation in ALK(+) CD30(+) lymphoma cells by the Hsp90 antagonist 17-allylamino,17- demethoxygeldanamycin Cancer Res 62 1559 1566 1:CAS:528:DC%2BD38Xit1Kgsr0%3D 11888936
25. U. Banerji A. O'Donnell M. Scurr, et al. 2005 Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino,17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 4152 4161 10.1200/JCO.2005.00.612 1:CAS:528:DC%2BD2MXmt1elsrY%3D 15961763 (Pubitemid 46211321)
26. B.K. Eustace D.G. Jay 2004 Extracellular roles for the molecular chaperone, hsp90 Cell Cycle 3 1098 1100 1:CAS:528:DC%2BD2MXntVantb0%3D 15326368
27. T. Shimamura A.M. Lowell J.A. Engelman G.I. Shapiro 2005 Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins Cancer Res 65 6401 6408 10.1158/0008-5472.CAN-05-0933 1:CAS:528:DC%2BD2MXmt1egtLw%3D 16024644 (Pubitemid 40994428)
28. S. Pennacchietti P. Michieli M. Galluzzo, et al. 2003 Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene Cancer Cell 3 347 361 10.1016/S1535-6108(03)00085-0 12726861 (Pubitemid 38340304)
29. V. Georget B. Terouanne J.-C. Nicolas C. Sultan 2002 Mechanism of antiandrogen action: key role of Hsp90 in conformational change and transcriptional activity of the androgen receptor Biochemistry 41 11824 11831 10.1021/bi0259150 1:CAS:528:DC%2BD38Xms1Cgtrg%3D 12269826
30. E. Hur H.H. Kim S.M. Choi, et al. 2002 Reduction of hypoxia-induced transcription through the repression of hypoxia-inducible factor-1alpha/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol Mol Pharmacol 62 975 982 10.1124/mol.62.5.975 1:CAS:528:DC%2BD38XosVKjur8%3D 12391259 (Pubitemid 35222488)
31. D. Zagzag M. Nomura D.R. Friedlander, et al. 2003 Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion J Cell Physiol 196 394 402 10.1002/jcp.10306 1:CAS:528:DC%2BD3sXltlSmtrY%3D 12811834 (Pubitemid 36775888)
32. S. Modi A.T. Stopeck M.S. Gordon, et al. 2007 Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410 5417 10.1200/JCO.2007.11.7960 1:CAS:528:DC%2BD1cXnvVCisQ%3D%3D 18048823 (Pubitemid 350232217)
33. M. Jhawer S. Goel A.J. Wilson, et al. 2008 PIK3-CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab Cancer Res 68 1953 1961 10.1158/0008-5472.CAN-07-5659 1:CAS:528:DC%2BD1cXjtFOhtro%3D 18339877 (Pubitemid 351416582)
34. L.R. Kelland S.Y. Sharp P.M. Rogers, et al. 1999 DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat shock protein 90 J Natl Cancer Inst 91 1940 1949 10.1093/jnci/91.22.1940 1:CAS:528:DyaK1MXotVaitr8%3D 10564678
35. H. Machida Y. Matsumoto M. Shirai N. Kubota 2003 Geldanamycin, an inhibitor of Hsp90, sensitizes human tumour cells to radiation Int J Radiat Biol 79 973 980 10.1080/09553000310001626135 1:CAS:528:DC%2BD2cXnvFam 14713575 (Pubitemid 38147058)
36. C. DeBoer P.A. Meulman R.J. Wnuk D.H. Peterson 1970 Geldanamycin, a new antibiotic J Antibiot (Tokyo) 23 442 447 1:CAS:528:DyaE3MXhtFyltQ%3D%3D
37. M.J. Egorin T.F. Lagattuta D.R. Hamburger, et al. 2002 Pharmacokinetics, tissue distribution, and metabolism of 17-(dimethylaminoethylamino)-17- demethoxygeldanamycin (NSC 707545) in CD2F1 mice and Fischer 344 rats Cancer Chemother Pharmacol 49 7 19 10.1007/s00280-001-0380-8 1:CAS:528: DC%2BD3MXptFClurs%3D 11855755
38. S. Chandarlapaty A. Sawai Q. Ye, et al. 2008 SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers Clin Cancer Res 14 240 248 10.1158/1078-0432.CCR-07- 1667 1:CAS:528:DC%2BD1cXoslGq 18172276 (Pubitemid 351378001)
39. S.M. Roe C. Prodromou R. O'Brien, et al. 1999 Structural basis for inhibition of the Hsp90 molecular chaperone by the anti-tumor antibiotics radicicol and geldanamycin J Med Chem 42 260 266 10.1021/jm980403y 1:CAS:528:DyaK1MXhslOlsg%3D%3D 9925731 (Pubitemid 29069861)
40. W.G. An T.W. Schulte L.M. Neckers 2000 The heat shock protein 90 antagonist geldanamycin alters chaperone association with p210bcr-abl and v-src proteins before their degradation by the proteasome Cell Growth Differ 11 355 360 1:CAS:528:DC%2BD3cXltlGltrg%3D 10939589
41. A. Kamal L. Thao J. Sensintaffar, et al. 2003 A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors Nature 425 407 410 10.1038/nature01913 1:CAS:528:DC%2BD3sXnsV2kt7w%3D 14508491 (Pubitemid 37187270)
42. S. Tsutsumi B. Scroggins F. Koga, et al. 2008 A small molecule cell-impermeant Hsp90 antagonist inhibits tumor cell motility and invasion Oncogene 27 2478 2487 10.1038/sj.onc.1210897 1:CAS:528:DC%2BD1cXksVKlu7k%3D 17968312 (Pubitemid 351521101)
43. T. Taldone A. Gozman R. Maharaj G. Chiosis 2008 Targeting Hsp90: small-molecule inhibitors and their clinical development Curr Opin Pharmacol 8 370 374 10.1016/j.coph.2008.06.015 1:CAS:528:DC%2BD1cXhtFCktL7J 18644253
44. T. Zhang A. Hamza X. Cao, et al. 2008 A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells Mol Cancer Ther 7 162 170 10.1158/1535-7163.MCT-07-0484 1:CAS:528:DC%2BD1cXmsVyhtQ%3D%3D 18202019
45. R.K. Ramanathan M.J. Egorin J.L. Eiseman, et al. 2007 Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers Clin Cancer Res 13 1769 1774 10.1158/1078-0432.CCR-06-2233 1:CAS:528:DC%2BD2sXivV2gt7c%3D 17363531 (Pubitemid 46952944)
46. J.L. Grem G. Morrison X.D. Guo, et al. 2005 Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors J Clin Oncol 23 1885 1893 10.1200/JCO.2005.12.085 1:CAS:528: DC%2BD2MXjt1Cku78%3D 15774780 (Pubitemid 46211366)
47. S. Pacey R. Wilson M. Walton, et al. 2007 A phase I of the heat shock protein 90 (HSP90) inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG, alvespimycin) administered weekly [abstract 3568] Proc Annu Meet Am Soc Clin Oncol 25 154
48. A. Elfiky W. Saif M. Beeram, et al. 2008 BIIB021, an oral synthetic non ansamycin Hsp90 inhibitor: phase I experience Proc Am Soc Clin Oncol 26 2503
49. P. Haluska D. Toft S. Steinmetz, et al. 2004 A phase I trial of gemcitabine (Gem), 17-allylaminogeldanamcyin (17-AAG) and cisplatin (CDDP) in solid tumor patients [abstract 3058] Proc Annu Meet Am Soc Clin Oncol 23 209
50. U. Banerji A. O'Donnell M. Scurr, et al. 2005 Phase I pharmacokinetic and pharmacodynamic study of 17-allylamino, 17-demethoxygeldanamycin in patients with advanced malignancies J Clin Oncol 23 4152 4161 10.1200/JCO.2005.00.612 1:CAS:528:DC%2BD2MXmt1elsrY%3D 15961763 (Pubitemid 46211321)
51. A. Wagner J. Morgan R. Chugh, et al. 2008 Inhibition of heat shock protein 90 (Hsp90) with a novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from a phase I trial [abstract 10503] Proc Annu Meet Am Soc Clin Oncol 26 55
52. S. Modi A.T. Stopeck M.S. Gordon, et al. 2007 Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol 25 5410 5417 10.1200/JCO.2007.11.7960 1:CAS:528:DC%2BD1cXnvVCisQ%3D%3D 18048823 (Pubitemid 350232217)
53. D.B. Solit I. Osman D. Polsky, et al. 2008 Phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with metastatic melanoma Clin Cancer Res 14 8302 8307 10.1158/1078-0432.CCR-08-1002 1:CAS:528: DC%2BD1cXhsV2it7nP 19088048
54. E.I. Heath M. Gaskins H.C. Pitot, et al. 2005 A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer Clin Prostate Cancer 4 138 141 1:CAS:528: DC%2BD28XhslWqsrs%3D 16197617